SANTA CRUZ BIOTECHNOLOGY, INC.

FEZ1 siRNA (h): sc-37410

BACKGROUND

Frequent loss of heterozygosity (LOH) at human chromosome 8p21.3 is associated with various tumors including prostate and breast cancer. The 8p21.3 region contains the FEZ1 gene which is altered in tumors of the esophagus, prostate and breast. The FEZ1 protein (also known as leucine zipper putative tumor suppressor or LZTS1) contains a DNA-binding leucine zipper motif. FEZ1 is expressed in normal breast and prostate cell, but alterations in FEZ1 expression result in abnormal cell growth. The absence of FEZ1 expression is characteristic of breast and prostate cancer cell lines as well as primary breast and prostate tumors. This absence of FEZ1 may be due to several factors including mutations in the FEZ1 gene or hypermethylation of the CpG island flanking the FEZ1 promoter region. FEZ1 acts as a negative regulator of cell growth. During cell-cycle progression, FEZ1 localizes to microtubule components and is hyperphosphorylated by cAMP-dependent kinase.

REFERENCES

1. Macoska, J.A., et al. 1995. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 55: 5390-5395.
2. Kagan, J., et al. 1995. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11: 2121-2126.
3. Anbazhagan, R., et al. 1998. Allelic loss of chromosomal arm 8p in breast cancer progression. Am. J. Pathol. 152: 815-819.
4. Ishii, H., et al. 1999. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc. Natl. Acad. Sci. USA 96: 3928-3933.
5. Ishii, H., et al. 2001. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc. Natl. Acad. Sci. USA 98: 10374-10379.
6. Vecchione, A., et al. 2001. Fez1/lzts1 alterations in gastric carcinoma. Clin. Cancer Res. 7: 1546-1552.
7. Cabeza-Arvelaiz, Y., et al. 2001. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20: 4169-4179.

CHROMOSOMAL LOCATION

Genetic locus: LZTS1 (human) mapping to 8p21.3.

PRODUCT

FEZ1 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see FEZ1 shRNA Plasmid (h): sc-37410-SH and FEZ1 shRNA (h) Lentiviral Particles: sc-37410-V as alternate gene silencing products.

For independent verification of FEZ1 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-37410A, sc-37410B and sc-37410C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

FEZ1 siRNA (h) is recommended for the inhibition of FEZ1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

FEZ1 (E-12): sc-393768 is recommended as a control antibody for monitoring of FEZ1 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor FEZ1 gene expression knockdown using RT-PCR Primer: FEZ1 (h)-PR: sc-37410-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.